Compare RNW & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | VERA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 3.0B |
| IPO Year | 2021 | 2021 |
| Metric | RNW | VERA |
|---|---|---|
| Price | $6.84 | $33.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $7.00 | ★ $81.30 |
| AVG Volume (30 Days) | 2.3M | ★ 2.3M |
| Earning Date | 06-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.50 | $472.48 |
| P/E Ratio | $14.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $23.05 |
| 52 Week High | $8.24 | $56.05 |
| Indicator | RNW | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 48.37 |
| Support Level | $6.78 | $33.43 |
| Resistance Level | $6.85 | $36.89 |
| Average True Range (ATR) | 0.03 | 1.96 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 55.00 | 39.83 |
ReNew Energy Global PLC is a developer and operator of clean energy projects. Additionally, it provides clean energy solutions and value-added energy offerings through digitalization, storage, and carbon market services that are increasingly integral to addressing climate change. The company has two reportable segments: Generation and sale of renewable power and Manufacturing of power equipment. The majority of its revenue is generated from the Generation and sale of renewable power segment, which reflects the revenue earned from its utility-scale wind energy projects, solar energy projects, and hydro energy projects. The Manufacturing of power equipment segment relates to the manufacturing of solar panels and modules. Geographically, all of its material revenues are generated from India.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.